Duchenne Muscular Dystrophy Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Duchenne Muscular Dystrophy Treatment Market is segmented by Therapeutic Approach (Molecular-based Therapies, Steroid Therapy, and Other Therapeutic Approaches), and Geography.

Market Snapshot

Duchenne Muscular Dystrophy Treatment Market Overview
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: North America
Largest Market: North America
CAGR: 11.1 %
Duchenne Muscular Dystrophy Treatment Market Major Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The propelling factors for the growth of the Duchenne muscular dystrophy (DMD) treatment market include the rising disease burden of Duchenne muscular dystrophy, increasing investments in biopharmaceutical R&D to release novel disease therapies, and increasing awareness campaigns for DMD.

Currently, there is an increase in the number of clinical trials for testing the future treatment for Duchenne muscular dystrophy. The only accepted pharmacological therapy for the treatment of DMD is corticosteroid-based anti-inflammatory treatment. The pharmaceutical drug discovery and development have also grown rapidly in the past few years. As there have been great breakthroughs in technology in the last few years that may facilitate research processes and as the explosion of science in understanding the causes of diseases has made target selection more rational than ever, almost all major companies are now concentrating on R&D, which is likely to have a major impact on the market in the coming years.

Furthermore, with increasing awareness among people and with the government’s urgency for the treatment of the disease, there is a big opportunity for the companies to conduct their trails and for new drugs launches, due to which, the market is expected to grow in the coming years.

Scope of the Report

As per the scope of the report, Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness. It is a rare muscle disease, which majorly affects males. There are novel drugs and therapies, disease-modifying, and mutation-specific therapies that are some of the emerging major breakthroughs in the DMD treatment market.

By Therapeutic Approaches
Molecular-based Therapies
Mutation Suppression
Exon Skipping
Steroid Therapy
Other Therapeutic Approaches
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle East & Africa
South Africa
Rest of Middle East & Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Exon-skipping Segment is Expected to Dominate Duchenne Muscular Dystrophy Treatment Market

Duchenne muscular dystrophy is mostly caused by the internal deletions in the gene for dystrophin, a protein essential for maintaining muscle cell membrane integrity. One of the potential therapeutic method is to mask an exon close to the site where the others are missing, so that the remaining exons can join together. Exon-skipping approach signifies one of the most capable therapeutic approaches that aim to restore the expression of a shorter but functional dystrophin protein.

Moreover, market players are focusing on frequent launches in exon skipping technology which is a significant factor driving the segment thereby propelling the market growth. For instance, In December 2019, Sarepta’s exon skipping drug, VYONDYS 53 (golodirsen) has been approved by the Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy.

Duchenne Muscular Dystrophy Treatment Market Trends

North American Region holds the Largest Market Share and is Believed to Follow the Same Trend Over the Forecast Period

North America dominates the global Duchenne muscular dystrophy market, due to new product innovations, high healthcare expenditure, and government awareness programs. The United States has dominated the regional market and is projected to maintain its lead, owing to the rising disease incidence and anticipated launch of promising pipeline candidates. In addition, the market is expected to grow with increasing clinical trials around the world, especially in the United States and Europe. According to the FDA in 2017, the Emflaza (deflazacort) tablets and oral suspension were approved to treat DMD patients aged 5 years and above. Emflaza is a corticosteroid that works by decreasing inflammation and reducing the activity of the immune system.

Duchenne Muscular Dystrophy Treatment Market Growth

Competitive Landscape

With increasing campaigns and awareness programs, the number of patients is expected to come down, and hence, many companies are conducting campaign programs that help to improve focus on medicines for DMD treatment. There are also very few companies for new drug research for rare diseases because it needs bigger funds. Therefore, the market is not well established in many other therapeutic areas. However, it is expected to experience high growth and expand during the forecast period.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Disease Burden of Duchenne Muscular Dystrophy (DMD)

      2. 4.2.2 Increasing Investments in Research and Development of Novel Therapies for DMD

      3. 4.2.3 Increasing Awareness Campaigns for DMD

    3. 4.3 Market Restraints

      1. 4.3.1 Lack of Standardization to Measure Clinical Efficacy Across All Stages of DMD

      2. 4.3.2 Stringent Regulatory Framework

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Therapeutic Approaches

      1. 5.1.1 Molecular-based Therapies

        1. Mutation Suppression

        2. Exon Skipping

      2. 5.1.2 Steroid Therapy

        1. Corticosteroids

      3. 5.1.3 Other Therapeutic Approaches

    2. 5.2 Geography

      1. 5.2.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.2.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.2.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.2.4 Middle East & Africa

        1. GCC

        2. South Africa

        3. Rest of Middle East & Africa

      5. 5.2.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 BioMarin

      2. 6.1.2 Fibrogen Inc.

      3. 6.1.3 Nobelpharma Co. Ltd

      4. 6.1.4 NS Pharma Inc.

      5. 6.1.5 Pfizer Inc.

      6. 6.1.6 PTC Therapeutics

      7. 6.1.7 Santhera Pharmaceuticals

      8. 6.1.8 Sarepta Therapeutics

      9. 6.1.9 F. Hoffmann-La Roche AG

      10. 6.1.10 ReveraGen BioPharma

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Duchenne Muscular Dystrophy Treatment Market market is studied from 2018 - 2026.

The Duchenne Muscular Dystrophy Treatment Market is growing at a CAGR of 11.1% over the next 5 years.

North America is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Pfizer Inc., Sarepta Therapeutics, PTC Therapeutics, FibroGen Inc., F. Hoffmann-La Roche AG are the major companies operating in Duchenne Muscular Dystrophy Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!